Skip to content

Quick ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.1×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-1.1×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
2.6×+0.3×
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
6.6×-1.2×
AbbVie logo
AbbVieABBV
0.7×0.0×
Regenxbio logo
RegenxbioRGNX
2.6×-0.3×

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$602.22M+215%
Enterprise value$550.27M+574%
P/S6.8×-8,306×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0.0×
Current ratio9.3×-3.0×

Where this comes from

Calculated from 4D Molecular Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 4D Molecular Therapeutics's quick ratio?
4D Molecular Therapeutics (FDMT) reported quick ratio of 9.3× in Q1 2026.
How has 4D Molecular Therapeutics's quick ratio changed year-over-year?
4D Molecular Therapeutics's quick ratio decreased by 24.5% year-over-year, from 12.4× to 9.3×.
What is the long-term trend for 4D Molecular Therapeutics's quick ratio?
Over 5 years (2020 to 2025), 4D Molecular Therapeutics's quick ratio has grown at a -11.1% compound annual growth rate (CAGR), from 16.9× to 9.4×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.